Confuses finasteride's enzyme inhibition with androgen receptor antagonism

5α-Reductase Inhibitors (Finasteride, Dutasteride)

5α-Reductase inhibitors (finasteride, dutasteride) block the enzyme that converts testosterone into dihydrotestosterone (DHT), a more potent androgen responsible for prostate growth and male-pattern hair loss, and USMLE Step 1 tests this drug class at the mechanism level and at the clinical application level. These drugs treat BPH and androgenetic alopecia by starving androgen-sensitive tissue of DHT while leaving circulating testosterone largely intact. The exam specifically distinguishes enzyme inhibition from receptor blockade, and covers PSA interpretation and teratogenicity precautions.

The exam loves to drop finasteride into a vignette about BPH management or prostate cancer screening and then ask you to interpret a lab value or make a clinical decision. The tricky part isn't knowing what finasteride does in isolation — it's applying that knowledge when a patient's PSA comes back 'normal' and you have to recognize that the number is artifactually suppressed. Finasteride roughly halves serum PSA, so a measured value of 2 ng/mL should be read as ~4 ng/mL for screening purposes. Missing this correction is one of the most commonly tested gaps on Step 1 for this drug.

A second high-yield angle is teratogenicity. Finasteride is teratogenic to male fetuses because DHT is required for normal virilization of external genitalia. The exam tests whether you know that even pregnant women handling crushed or broken tablets face risk from transdermal absorption — not just patients taking the drug orally. These two angles (PSA correction and teratogenic precautions) are where most students lose points, not on the basic mechanism.

From real student decks

71%have cards covering this topic

58%have mature cards

Common misconceptions

Common mistake

Gap: Missing that finasteride halves PSA, requiring correction when interpreting prostate cancer screening

Finasteride reduces serum PSA by approximately 50%, so a measured PSA must be doubled to estimate the true value when screening for prostate cancer in patients on finasteride.

Finasteride shrinks prostatic epithelium by depleting DHT, and as a side effect it reduces PSA secretion by roughly half — even in the presence of early prostate cancer. If you read a PSA of 2 ng/mL at face value in a patient on finasteride, you're effectively ignoring a true value closer to 4 ng/mL. The clinical rule is simple: double the measured PSA before interpreting it in any patient on 5α-reductase inhibitors.

Common mistake

Wrong: Finasteride blocks the androgen receptor directly like flutamide.

Right: Finasteride inhibits 5α-reductase, preventing conversion of testosterone to the more potent DHT, rather than blocking the androgen receptor.

Finasteride works upstream of the androgen receptor — it inhibits the enzyme 5α-reductase, blocking the conversion of testosterone to DHT. Flutamide and bicalutamide are androgen receptor antagonists that work downstream by competing with DHT for receptor binding. These are completely different mechanisms, and the distinction matters: finasteride doesn't block all androgenic activity, just the DHT-dependent portion, which is why testosterone levels actually rise slightly on finasteride.

Common mistake

Gap: Missing that finasteride poses teratogenic risk to male fetuses via skin contact in pregnant women

Finasteride is teratogenic to male fetuses (inhibits virilization) and pregnant women must not handle crushed tablets due to transdermal absorption risk.

DHT is required during fetal development for differentiation of male external genitalia from the urogenital sinus and tubercle. If a pregnant woman is exposed to finasteride — even through skin contact with a crushed tablet — enough drug can be absorbed transdermally to inhibit 5α-reductase in a male fetus, resulting in ambiguous genitalia or undervirilization. This is why finasteride tablets are film-coated and why pregnant women are instructed to avoid handling broken or crushed tablets entirely.

Guided session

Stuck on this? An AI tutor that probes your understanding and catches where your reasoning breaks.

Start a session →

Free Deck audit

Already run Anki? See if your deck covers this topic.

Upload your deck →

What the exam tests

Understand the mechanism of 5α-reductase inhibitors: they prevent conversion of testosterone to DHT at the enzyme level, which is distinct from androgen receptor blockers like flutamide that work downstream at the receptor.
Know how finasteride affects PSA interpretation: because it suppresses PSA by approximately 50%, a measured PSA on a patient taking finasteride must be doubled to estimate the true baseline value for prostate cancer screening purposes.
Recognize the teratogenic risk of finasteride to male fetuses and understand that pregnant women must not handle crushed or broken tablets due to the risk of transdermal absorption causing impaired virilization.

Can you avoid these mistakes?

A 62-year-old man with BPH has been taking finasteride for 2 years. His PSA comes back at 2.8 ng/mL. His urologist says this is reassuring. Is the urologist correct, and what is the appropriate way to interpret this value?

How does finasteride's mechanism differ from flutamide's? What happens to serum testosterone levels in a patient taking finasteride, and why?

A pregnant woman calls her OB saying she accidentally broke her husband's finasteride tablet while organizing his medications and may have touched the powder. Should she be concerned? What is the relevant risk and why?

A patient is started on finasteride for androgenetic alopecia. Six months later his PSA is measured for the first time as part of a routine screen and is 1.4 ng/mL. What value should be used to interpret his prostate cancer risk?

5α-Reductase Inhibitors (Finasteride, Dutasteride)

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics